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Special Report
Research Priorities in Hypertrophic Cardiomyopathy
Report of a Working Group of the National Heart, Lung, and
Blood Institute
Thomas Force, MD; Robert O. Bonow, MD; Steven R. Houser, PhD; R. John Solaro, PhD;
Ray E. Hershberger, MD; Bishow Adhikari, PhD; Mark E. Anderson, MD, PhD; Robin Boineau, MD;
Barry J. Byrne, MD, PhD; Thomas P. Cappola, MD; Raghu Kalluri, MD, PhD;
Martin M. LeWinter, MD; Martin S. Maron, MD; Jeffery D. Molkentin, PhD; Steve R. Ommen, MD;
Michael Regnier, PhD; W.H. Wilson Tang, MD; Rong Tian, PhD; Marvin A. Konstam, MD;
Barry J. Maron, MD; Christine E. Seidman, MD
Hypertrophic cardiomyopathy (HCM) is a myocardial dis-order characterized by left ventricular (LV) hypertrophy
without dilatation and without apparent cause (ie, it occurs in the
absence of severe hypertension, aortic stenosis, or other cardiac
or systemic diseases that might cause LV hypertrophy). Numer-
ous excellent reviews and consensus documents provide a
wealth of additional background.1–8 HCM is the leading cause of
sudden death in young people and leads to significant disability
in survivors. It is caused by mutations in genes that encode
components of the sarcomere. Cardiomyocyte and cardiac hy-
pertrophy, myocyte disarray, interstitial and replacement fibro-
sis, and dysplastic intramyocardial arterioles characterize the
pathology of HCM. Clinical manifestations include impaired
diastolic function, heart failure, tachyarrhythmia (both atrial and
ventricular), and sudden death. At present, there is a lack of
understanding of how the mutations in genes encoding sarco-
mere proteins lead to the phenotypes described above. Current
therapeutic approaches have focused on the prevention of
sudden death, with implantable cardioverter defibrillator place-
ment in high-risk patients. But medical therapies have largely
focused on alleviating symptoms of the disease, not on altering
its natural history. The present Working Group of the National
Heart, Lung, and Blood Institute brought together clinical,
translational, and basic scientists with the overarching goal of
identifying novel strategies to prevent the phenotypic expression
of disease. Herein, we identify research initiatives that we hope
will lead to novel therapeutic approaches for patients with HCM.
Epidemiology
The epidemiology of HCM suggests that it is present in 1 in
500 adults.9 Because of the delay in phenotypic expression of the
disease, HCM is not commonly recognized clinically in young
children, but when it is, it is much more frequently recognized in
males.10 This is likely due to greater penetrance in young
males.11,12 HCM is underdiagnosed clinically in blacks and in
women, yet women tend to present with more marked heart
failure than men when they are diagnosed later in life.13,14 There
is no overall difference in mortality, including sudden cardiac
death, between men and women, although sudden cardiac death
on the athletic field predominantly occurs in men.
Genetic Cause
Extensive investigation has shown that at least 50% of HCM
cases can be traced to a specific genetic cause. This probably
underestimates the true percentage of genetically based
HCM, because current mutation-screening platforms typi-
cally examine only 8 to 10 genes because of unfavorable
cost-benefit assessments. For example, current platforms do
not examine titin (owing to its size) or myozenin-2 (because
relatively few mutations have been defined in this gene).15
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Moreover, when strict clinical criteria are used for diagnosis,
including family history, mutation detection approaches 70%.
HCM is a genetic disease of sarcomere proteins,5,16 with
mutations in the genes that encode -myosin heavy chain
(MYH7) and myosin binding protein C (MYBPC3) accounting
for 80% to 85% of cases with identified mutations in most
series.4,17–19 Mutations in the troponins cardiac troponin T
(TNNT2) and troponin I (TNNI3) and -tropomyosin (TPM1)
are also relatively common, collectively representing 10% to
15% of additional genetic causes for all HCM cases.4,17,19 These
and the myosin light chains (MYL2, MYL3) and -cardiac actin
(ACTC) are the 8 genes most commonly involved in HCM.
Rare Genetic Causes
Mutations in several other genes that encode sarcomere or
sarcomere-related proteins have been implicated in HCM,
including cardiac troponin C (TNNC1), -myosin heavy
chain (MYH6), and cardiac myosin light chain kinase 2
(MYLK2). In addition, several other genes that encode non-
sarcomere proteins, including caveolin 3 (CAV3), calreticulin
(CALR3), junctophilin-2 (JPH2), phospholamban (PLN), and
the mitochondrial tRNA-encoding genes MTTG and MTTI,
produce clinical features that mimic HCM.4,20 The relation-
ship of HCM caused by sarcomere protein gene mutations to
these disorders is unclear.5,16
Unknown Causes
The apparent absence of mutations in patients with a clinical
diagnosis of HCM indicates an important gap in our knowl-
edge. Mutation testing can be particularly uninformative in 3
clinical scenarios in which family history is negative: (1)
Hypertrophy that occurs very early in childhood; (2) hyper-
trophy that is only recognized after middle age; and (3)
hypertrophy that is limited to the ventricular apex.21 The
cause of these conditions is not clear.
Disease Mechanisms
The disease mechanisms of HCM remain incompletely under-
stood. Postulated mechanisms include (1) a dominant negative
function (ie, a “poison peptide,” wherein the mutant gene
encodes a protein that interferes with the function of the normal
allele); (2) haploinsufficiency (leading to an insufficient quantity
of the normally functioning sarcomere protein); and/or (3)
impaired myocardial energetics and decreased energy re-
serve.8,22,23 The lack of a definitive link between mutations and
an understanding of the pathogenesis/molecular mechanisms
that drive the expression of the HCM phenotype is a significant
gap in our understanding of the disease.
Clinical Genetics
Allelic heterogeneity (each family having a so-called private
mutation) is particularly common in HCM. Approximately
500 mutations have been noted in the medical literature, but
the number of identified mutations in various private data-
bases suggests the true number is more than 1000. HCM
demonstrates age-dependent penetrance, affecting 50% to 80%
and 95% of individuals by age 30 years and ages 50 to 60 years,
respectively.24 Recent estimates of 1% annual mortality in HCM
differ significantly from earlier estimates (3% to 6%) that were
based on referral populations of high-risk groups to HCM
centers.25–27 Survival to 75 years or beyond has been estimated
in 25% of an unselected HCM cohort.28
Compound Heterozygosity
Two to five percent of patients with HCM harbor 2 mutations
(compound or double heterozygosity) or are homozygous for
a mutation,4,18,29,30 and these patients display more severe
and/or earlier onset of disease.29,30
Genotype/Phenotype Relationships
Despite the significant clinical heterogeneity observed even
for the same mutation within families or between fami-
lies,31–35 as well as the variable penetrance, which alters
clinical onset and severity of disease, genotype/phenotype
relationships of sarcomere gene mutations clearly have ad-
vanced our understanding of the disease and, in some cases,
have allowed identification of relatively low- versus high-risk
patients.36,37 Some genotype/phenotype relationships that
have stood the test of time include MYH7 mutations, which
are associated with earlier onset and more extensive hyper-
trophy.8,33,35 More specifically, the myosin 403 mutation is
associated with increased risk of heart failure and sudden
death, and the myosin 719 mutation leads to a marked
increase in heart failure. Others include the relatively limited
hypertrophic response with TNNT2 mutations34,38,39 and the
incomplete penetrance and relatively later onset of HCM
from MYBPC3 mutations.31,36,40 That said, multiple poorly
understood mechanisms contribute to heterogeneity of pre-
sentation, and these include environmental inputs, sex,10 and
genetic and epigenetic modifiers.
Key Morphological and Clinical Components
of Genetically Mediated HCM
Cardiomyocyte and cardiac hypertrophy, myocyte disarray,
interstitial and replacement fibrosis, and dysplastic intramyo-
cardial arterioles characterize the pathology of HCM. Clinical
manifestations include impaired diastolic function,
tachyarrhythmia (both atrial and ventricular), and sudden
death.41–44 Accepted risk factors for sudden cardiac death
include prior cardiac arrest from ventricular fibrillation,
spontaneous sustained ventricular tachycardia, family history
of premature sudden death, unexplained syncope, LV wall
thickness 30 mm, abnormal blood pressure response to
exercise, and nonsustained ventricular tachycardia.28,43 Addi-
tional predictors include the presence of LV apical aneurysms
and the end stage of disease.45,46
A consensus document1 and review47 of clinical manage-
ment of arrhythmias and sudden cardiac death in HCM are
available. Clinically apparent atrial fibrillation develops in at
least 20% of patients with HCM,48 but the true incidence is
likely higher than that. Atrial fibrillation is a risk factor for
thromboembolic disease, including stroke.1 Molecular mech-
anisms that regulate the phenotypic expression of the various
pathologies and how these might drive arrhythmogenesis in
HCM are poorly understood.
Genetic Causes of LV Hypertrophy Not
Involving Sarcomere Mutations
LV hypertrophy can result from gene mutations that alter
proteins with functions that are unrelated to the sarcomere. These
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include Fabry disease, glycogen storage disorders (PRKAG2
cardiomyopathy and Pompe disease), lysosomal disorders
(X-linked lysosome-associated membrane protein gene
cardiomyopathy), and several syndromes (ie, Noonan,
lentigines, ECG abnormalities, ocular hypertelorism, pul-
monary valve stenosis, abnormal genitalia, retardation of
growth, and deafness [LEOPARD], and Costello). The
clinical manifestations and patient courses associated with
these are different from HCM.8,17,49 –51 These phenocopies
are not discussed further herein.
Rationale for Investing in Research on HCM
The rationale for investing in research in HCM is supported
by the following: (1) HCM is the most common genetic heart
disease and affects individuals at every age; (2) HCM is the
most common cause of sudden death in young people; (3)
HCM is an important cause of heart failure disability; (4)
HCM can be viewed as a paradigm for the potential oppor-
tunities provided by harnessing modern genetic science in
medicine to make gene-based diagnosis and prediction a
reality; (5) gaps in our basic understanding of mechanisms of
disease are substantial, but already, insights provided by
studies in patients and in animal models of HCM suggest
creative strategies to alter the natural history of this disease;
and (6) these insights also promise a greater understanding of
the molecular pathophysiology of other, nongenetic causes of
hypertrophy. Thus, we believe that there are unparalleled
opportunities in the immediate and near future to translate
basic insights about HCM into new clinical models for
diagnosis, prevention, and therapy.
Critical Deficits in Our Understanding of
HCM Pathogenesis Define Research Initiatives
In the online-only Data Supplement to this report, we define key
deficits in our understanding of HCM, thereby leading into a
delineation of research initiatives for the future. The areas of
research will be broken down into clinical, translational, and
basic science sections, but these divisions are clearly arbitrary
and only serve as an organizational (and not operational) tool. In
fact, we will strive to maintain connections among the 3
divisions, focusing on common deficits in our understanding.
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